The 5-state Markov model utilized predictive regression equations and transition probabilities from the Framingham and PROCAM epidemiological studies. Patient characteristics were taken from the Lausanne Health Promotion Database which consisted of 9401 patients aged 18 to 79 years. Patients in the database were segmented according to their status of meeting the criteria of having MS, CMRF, and their age. Direct medical costs were accounted in 2005 Swiss Francs (CHF). Outcomes were projected over a lifetime horizon and discounted at 5% per annum. RESULTS: The presence of MS was projected to result in decreased LE by 2.29 years (16.27 vs 13.98 years) compared to individuals without the syndrome. The presence of MS was consistently associated with lower LE in all patient age groups. Direct medical costs of treating CVD complications in patients with MS were CHF 4413 higher than patients without the syndrome (CHF 8382 vs. CHF 3969). The largest differences in cost were estimated for patients aged above 75 years (CHF 11,744 vs. CHF 6707). CONCLUSIONS: On the basis of the NCEP/ATP III definition, our modeling analysis concludes that the presence of MS decreases LE (−2.29 years) and increases CVD costs (CHF 4413) per patient in the Swiss setting. These data suggest that the costs of future interventions targeted at the causes/management of MS could be offset by reduced CVD costs.
PCV36 A HEALTH ECONOMIC EVALUATION OF CONCOMITANT SURGICAL ABLATION FOR ATRIAL FIBRILLATION
Lamotte M 1 , Annemans L 2 , Siebert M 3 1 IMS Health, Brussel, Brabant, Belgium, 2 IMS Health, Brussels, Belgium, 3 St-Jude Medical, Zaventem, Vlaams Brabant, Belgium OBJECTIVES: Atrial fibrillation (AF) is the most common arrhythmic condition, with rising prevalence. AF increases stroke and mortality rates. Ablation (percutaneous and surgical) provides a more permanent solution to AF compared to drugs and reduces stroke and mortality rates. Performing surgical ablation (SA) concomitantly to cardiac surgery (CABG or valvular repair) only lengthens surgery with maximum 30 min without increasing complication rates. The aim of this study was to assess the cost-effectiveness of concomitant SA for permanent AF, with the UK as a case country. METHODS: A Markov model, comparing no ablation during surgery (NSA) with concomitant SA for AF, was developed in TreeAge. The initial cardiac surgery (with or without SA) can result in short-term complications (mortality, stroke, bleeding leading to re-surgery, and pacemaker implantation) or not. 4 different health states were defined: sinus rhythm without complications, AF without complications, history of stroke and death. Every 3 months (for a total of 5 years) the patient had a risk to die or to have a stroke or an AF recurrence. Clinical data were derived from published data (3month free of AF after SA 81% vs. 23% for NSA). Direct costs from the NHS (2006) perspective were used. The cost of SA was assumed to be GBP2500. Utility data (TTO) were obtained from published data and from the Euro Heart Survey (utility permanent AF = 0.78). Costs and effects were discounted at 3.5% annually. RESULTS: Over the 5-year modeling period SA resulted in 0.427 QALY gained (3.079 QALY vs. 2.652 QALY) for an additional cost of GBP2054 (GBP4567 vs. GBP2513). The incremental cost-effectiveness ratio (ICER) was GBP4810/ QALYG. Doubling the modelling period decreased ICER with 50%. Increasing utility of AF to 0.97 increased ICER to GBP19,106/QALYG. CONCLUSIONS: Compared to no ablation, concomitant SA is a cost-effective treatment for AF in the UK. Hypertension is a common condition leading to increased risk of excess mortality and morbidity from cardiovascular events (AMI and stroke). Furthermore, it is known that blood pressure reduction of 2-5 mmHg has an impact on the patients risk for cardiovascular events and mortality. In a double blinded RCT irbesartan 300 mg reduced systolic blood pressure by 16.4 mmHg while losartan 100 mg reduced blood pressure by 11.3 mmHg. P value was significant (p < 0.05). OBJECTIVE: To assess the cost-effectiveness of long-term treatment of hypertension with irbesartan vs. losartan in a Danish setting. METHODS: A Markov model was developed using the SCORE risk function to predict cardiovascular events depending on blood pressure level and other risk factors. The effect of irbesartan and losartan was taken from a RCT study with direct comparison (the Kassler-Taub study). In this study, irbesartan was also compared to no treatment. In the model, lifelong treatment was evaluated with either early intervention, when hypertension occurs (age 55), or late intervention after the occurrence of the first cardiovascular event. Health outcomes were number of cardiovascular events, life years and QALYs gained. Danish costs and epidemiological data were applied. RESULTS: Irbesartan was shown to be cost-saving vs. losartan (−€5.950/LYG). Compared to placebo, early intervention was shown to be more cost-effective relative to late intervention. CONCLUSIONS: Long-term treatment of hypertension with irbesartan can be cost-saving compared to treatment with losartan.
PCV38 COST MINIMIZATION ANALYSIS OF BIVALIRUDIN VERSUS HEPARIN PLUS PLANNED ABXICIMAB IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
Cequier Á 1 , Morís C 2 , Badia X 3 , Lara N 3 1 Hospital Universitario de Bellvitge. Universidad de Barcelona, Barcelona, Barcelona, Spain, 2 Hospital Universitario Central de Asturias, Asturias, Asturias, Spain, 3 Health Outcomes Research Europe, Barcelona, Spain OBJECTIVES: Bivalirudin, a selective thrombin inhibitor, has been approved as an alternative treatment to the use of heparin in patients undergoing percutaneous coronary intervention (PCI). The objective is to evaluate the efficiency measured as the health care costs savings, due to the replacement of the current heparin plus glycoprotein IIb/IIIa inhibition (abciximab) by bivalirudin in patients undergoing PCI. METHODS: Regarding the incidence of ischaemic events, it has been proved the equivalence between heparin plus inhibitors of glycoprotein and bivalirudin, noticing a smaller rate of bleeding complications in the group treated with bivalirudin (REPLACE 2). Based on this finding a cost minimization analysis (CMA) has been carried out focusing on the differential costs when using both treatments: the drug cost, the cost of major bleeding management (bleeding at puncture point and digestive bleeding). Two experts in inter-
